Dr. Haina Wang|
Position: Associate Professor
Address: Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Shandong University
44 Wenhuaxi Road, Jinan, 250012, P.R.China
1999 Bachelor’s degree in Pharmacy from Shandong University
2003 MS degree in Pharmaceutical Analysis from Shandong University
2011 PhD degree in Pharmaceutical Analysis from Zhejiang University;
2003-2006, Teaching Assistant, Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Shandong University
2006-2013, Lecturer, Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Shandong University
2013-present: Associate Professor, Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Shandong University
2013-2014: Visiting Scholar, Lab of Metabolism, National Cancer Institute, National Institutes of Health, USA
1. Drug metabolism-drug metabolizing enzymes and nuclei receptors
2. Analysis of chiral drugs and quality control of drugs
3. Metabolomics-mechanism of liver toxicity based on metabolomics methods
1. The effects of SNPs on the metabolism of chiral drugs based on the network of PXR-CYP. National Natural Science Foundation of China (81102504).
2. Studies on the mechanism of interaction between biomacromolecule and chiral compounds based on PXR-CYP network. Natural Science Foundation of Shandong Province (BS2013YY054).
3. Studies on the differences on the stereoselective glucuronidation between UGT wild type and mutants. Natural Science Foundation of Shandong Province (2009ZRA01070).
Main Research Publications
1. Fang ZZ, Tosh DK, Tanaka N, Wang HN, et al. Metabolic mapping of A3 adenosine receptor agonist MRS5980, Biochemical Pharmacology, 2015; 97(2):215-223.
2. Jia L, Hu C, Wang HN, et al. Chirality Influence of Zaltoprofen Towards UDP-Glucuronosyltransferases (UGTs) Inhibition Potential, Chirality, 2015; 27(6):359-363.
3. Fang ZZ, Wang HN, Cao YF, et al. Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT)2B7, Chirality, 2015; 27(3):189-193.
4. Wang HN, Fang ZZ, Zheng Y, et al. Metabolic profiling of praziquantel enantiomers. Biochemical Pharmacology, 2014; 90(2):166-178.
5. Wang HN, Dong SQ, Xu H, et al. Genetic variants in FTO associated with metabolic syndrome: a meta- and gene-based analysis. Mol. Biol. Rep., 2012; 39:5691-5698.
6. Fang SM, Wang HN, Zhao ZX, Wang WH, Immobilized enzyme reactors in HPLC and its application in inhibitor screening: A review, Journal of Pharmaceutical Analysis, 2012, 2(2):83-89.
7. Wang HN, Yuan LM, Zeng S. Characterizing the effect of UDP-Glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochemical Pharmacology, 2011; 82(11):1757-1763.
8. Wang HN, Ji JB, Zeng S. Biosynthesis and stereoselective analysis of (-)- and (+)-zaltoprofen glucuronide in rat hepatic microsomes and its application to the kinetic analysis. Journal of chromatography B, 2011; 879(24): 2430-2436.
Yuan LM, Liu Y, Wang HN,Cheng J, Zeng S, Evaluation the ADME properties of drug candidates by recombinant drug metabolizing enzymes, International Symposim of Quantitative Pharmacology in Drug Development and Regulation, Nanjing, China, 2007;October 29-31.
Yan Jun, Chen SL, Wang HN, Meta-Analysis of 5% Imiquimod and 0.5% Podophyllotoxin in the Treatment of Condylomata Acuminata. Dermatology 2006;213(3):218–223.